16
Jul

The blockbuster duo of GlaxoSmithKline and Theravance are pushing a new respiratory combo therapy into late-stage study, pooling the active ingredients from its last two approved COPD treatments to create a once-daily inhaler.

…read more

Source: GlaxoSmithKline and Theravance eye Phase III for another COPD contender

    

0 No comments